Barinthus Biotherapeutics Plc Stock Operating Margin
| BRNS Stock | 1.04 0.03 2.97% |
Barinthus Biotherapeutics plc fundamentals help investors to digest information that contributes to Barinthus Biotherapeutics' financial success or failures. It also enables traders to predict the movement of Barinthus Stock. The fundamental analysis module provides a way to measure Barinthus Biotherapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Barinthus Biotherapeutics stock.
| Last Reported | Projected for Next Year | ||
| Operating Profit Margin | (120.33) | (126.34) |
Barinthus | Operating Margin |
Barinthus Biotherapeutics plc Company Operating Margin Analysis
Barinthus Biotherapeutics' Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current Barinthus Biotherapeutics Operating Margin | (0.61) % |
Most of Barinthus Biotherapeutics' fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Barinthus Biotherapeutics plc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Barinthus Operating Margin Driver Correlations
Understanding the fundamental principles of building solid financial models for Barinthus Biotherapeutics is extremely important. It helps to project a fair market value of Barinthus Stock properly, considering its historical fundamentals such as Operating Margin. Since Barinthus Biotherapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Barinthus Biotherapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Barinthus Biotherapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
| Competition |
Barinthus Pretax Profit Margin
Pretax Profit Margin |
|
Based on the recorded statements, Barinthus Biotherapeutics plc has an Operating Margin of -0.6113%. This is 98.26% lower than that of the Biotechnology sector and 99.45% lower than that of the Health Care industry. The operating margin for all United States stocks is 88.91% lower than that of the firm.
Barinthus Operating Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Barinthus Biotherapeutics' direct or indirect competition against its Operating Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Barinthus Biotherapeutics could also be used in its relative valuation, which is a method of valuing Barinthus Biotherapeutics by comparing valuation metrics of similar companies.Barinthus Biotherapeutics is currently under evaluation in operating margin category among its peers.
Barinthus Fundamentals
| Return On Equity | -0.33 | ||||
| Return On Asset | -0.19 | ||||
| Operating Margin | (0.61) % | ||||
| Current Valuation | (51.6 M) | ||||
| Shares Outstanding | 40.23 M | ||||
| Shares Owned By Insiders | 10.98 % | ||||
| Shares Owned By Institutions | 46.22 % | ||||
| Number Of Shares Shorted | 12.37 K | ||||
| Price To Book | 0.26 X | ||||
| Price To Sales | 2.79 X | ||||
| Revenue | 802 K | ||||
| Gross Profit | (30.12 M) | ||||
| EBITDA | (71.06 M) | ||||
| Net Income | (73.63 M) | ||||
| Total Debt | 12.98 M | ||||
| Book Value Per Share | 4.03 X | ||||
| Cash Flow From Operations | (50.92 M) | ||||
| Short Ratio | 0.33 X | ||||
| Earnings Per Share | (1.49) X | ||||
| Target Price | 6.25 | ||||
| Number Of Employees | 130 | ||||
| Beta | -0.58 | ||||
| Market Capitalization | 41.84 M | ||||
| Total Asset | 214.51 M | ||||
| Retained Earnings | (176.59 M) | ||||
| Working Capital | 144.31 M | ||||
| Net Asset | 214.51 M |
About Barinthus Biotherapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Barinthus Biotherapeutics plc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Barinthus Biotherapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Barinthus Biotherapeutics plc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Barinthus Stock Analysis
When running Barinthus Biotherapeutics' price analysis, check to measure Barinthus Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Barinthus Biotherapeutics is operating at the current time. Most of Barinthus Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Barinthus Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Barinthus Biotherapeutics' price. Additionally, you may evaluate how the addition of Barinthus Biotherapeutics to your portfolios can decrease your overall portfolio volatility.